Dr. Reddy’s Laboratories Ltd: India’s Generic Genius or Form 483 Frequent Flyer?

1. At a Glance

One of India’s finest pharma exports, Dr. Reddy’s delivers ₹32K+ Cr in revenues, 26% operating margins, and global ANDA dominance. But the stock has slipped -5% YoY despite blockbuster profits. Is the R&D king undervalued?

2. Introduction with Hook

Imagine a doctor who writes prescriptions in 90 countries but still doesn’t get the love back home.

That’s Dr. Reddy’s Labs — with over 400 generic molecules, strong U.S. approvals, and cash-rich operations, it’s the brainy overachiever the market keeps forgetting at awards night.

• FY25 PAT: ₹5,725 Cr
• ROCE: 22.7%, P/E just 18.9x
• Q1 FY26 results coming July 23, 2025

Also: USFDA slapped 7 observations in July. Drama, as always.

3. Business Model (WTF Do They Even Do?)

5 Vertical Model:

1. Global Generics (83% of revenue):
   – 400+ generic drugs across U.S., India, EU, Russia, etc.
   – Strong in CNS, GI, anti-infectives
2. APIs:
   – Supplied to 60+ countries; backward integration ensures pricing power
3. Proprietary Products:
   – Differentiated formulations, biosimilars, OTC, dermatology, oncology
4. Custom Pharma Services (CPS):
   – CDMO for innovators
5. Biosimilars:
   – Pegfilgrastim, Rituximab in pipeline

Basically, they make the brain juice of pharma, and also the pill.

4. Financials Overview